TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin

Thrombosis Research

Volumn 77, Issue 2, 1995, Pages 175-185

  Hoppensteadt, Debra A ^a   Walenga, Jeanine M ^a   Fasanella, Anthony ^a   Jeske, Walter ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

heparin; intravenous; low molecular weight heparin; subcutaneous; tissue factor pathway inhibitor

Indexed keywords

ARDEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIPOPROTEINS; SWINE;

EID: 0028796872     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(95)91623-S     Document Type: Article

References (16)

1. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein
2. Inhibition of factor VIIa/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibition mechanisms
3. Regulation of coagulation by a multivalent kunitz-type inhibitor
4. Heparin induces the release of extrinsic coagulation pathway inhibitor (EPI)
5. Tissue factor pathway inhibitor
6. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor show that it consists of three tandem kunitz-type inhibitory domains
7. Recombinant human tissue factor pathway inhibitor
8. The significance of TFPI in clotting assays — comparison and combination with other anticoagulants
9. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation
10. Effect of tissue factor pathway inhibitor (TFPI) in the heptest and in an amidolytic anti factor Xa assay for LMW heparin
11. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
12. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor
13. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits
14. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model
15. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparin sulfate and heparin